SMMT

Summit Therapeutics Inc.

Price

$13.11

return (12m)

-48.28%

p/e

-12.13

p/bv

16.49

DIVIDEND YIELD

0.00%

SMMT price

Summit Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment SMMT

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-8.77%

3 months

-24.96%

1 year

-48.28%

2 years

7.02%

5 years

64.49%

10 years

80.83%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals SMMT

Valuation

P/E

-12.13

Sector -4.38

Industry -4.38

P/BV

16.49

Sector 2.02

Industry 2.02

P/Revenue (PSR)

Sector -4.40

Industry -4.40

EV/EBITDA

-43.98

Sector -263.09

Industry -263.09

EV/EBIT

-43.97

Sector -702.90

Industry -702.90

P/EBITDA

-11.99

Sector -4.39

Industry -4.39

P/EBIT

-11.98

Sector -4.73

Industry -4.73

P/Total Assets

13.81

Sector 1.49

Industry 1.49

P/Net Current Assets

17.36

Sector -11.70

Industry -11.70

P/Working Capital

16.83

Sector -3.19

Industry -3.19

EPS

-1.10

Sector -2.14

Industry -2.14

BVPS

0.81

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

0.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

0.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

0.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-135.89%

Sector -65.14%

Industry -65.14%

ROA

-113.81%

Sector -65.53%

Industry -65.53%

ROIC

-1,962.58%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

6.96

Sector 2.90

Industry 2.90

Net Debt / EBITDA

3.13

Sector -6.07

Industry -6.07

Net Debt / EBIT

3.13

Sector -8.26

Industry -8.26

Net Debt / Equity

-1.10

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.84

Sector 0.41

Industry 0.41

Liabilities/Assets

0.16

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

57.40%

Sector -

Industry -

Fundamentals SMMT

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
SMMT Summit Therapeutics Inc.	$13.11	-50.13%	0.00%	-12.13	16.49	-135.89%	0.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

SMMT Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Summit Therapeutics

Summit Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

6 years

Founded: 2020

2015

Time since IPO - 11 years

81

Employees

Summit Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $10.39 billion, with shareholders equity totaling $629.98 million.

The company employs approximately 81 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Summit Therapeutics Inc. reported $- in revenue, generating net income of $-856.08 million.

Key financial metrics include a P/E ratio of -12.13, a price-to-book (P/B) ratio of 16.49, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker SMMT.

Market cap

$10.39 billion

Net worth

$629.98 million

$629,980,000.00

Assets

$752.18 million

$752,180,000.00

Total Shares Outstanding

778.00 million

778,000,000

Average Daily Trading Volume

$4.94 million

$4,943,302.00

Sector

Health Care

Industry

Biotechnology

SMMT

SMMT revenue and profits

Financial Results SMMT

DRAG THE FRAME TO SEE MORE DATA

SMMT cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Summit Therapeutics (SMMT) today?

A cotação de Summit Therapeutics (SMMT) hoje está em US$ 13.11, com uma variação de -48.28% em relação ao último ano. A cotação de Summit Therapeutics (SMMT) iniciou o ano negociando na casa dos US$ 17.49 e hoje está em US$ 13.11. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Summit Therapeutics (SMMT) e dados de ações do Ibovespa e mercados internacionais.

Quando Summit Therapeutics (SMMT) paga dividendos?

Summit Therapeutics (SMMT) não distribuiu dividendos no último ano.

Is Summit Therapeutics (SMMT) a good investment?

Atualmente, Summit Therapeutics (SMMT) está cotada a US$ 13.11, com um P/L de -12.13, representando um desvio de -2,055% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de -48.28 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de -48.28%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Summit Therapeutics (SMMT) stock?

Investir em ações de Summit Therapeutics (SMMT) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Summit Therapeutics (SMMT) yield today?

A rentabilidade de Summit Therapeutics (SMMT) foi de -8.77% no último mês, -48.28% no último ano e 64.49% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Summit Therapeutics (SMMT) hoje, o investimento total seria de US$ 1,311.00, com base na cotação atual de US$ 13.11.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 678.05
Em 5 anos: US$ 2,156.46
Em 10 anos: US$ 2,370.68

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

SMMT

Summit Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment SMMT

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING SMMT WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Summit Therapeutics

Summit Therapeutics Inc.

United States

6 years

2015

81

PROFIT X PRICE SMMT

Financial Results SMMT

SMMT cash flow

Asset, Revenue and Profit Growth - SMMT

SMMT balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions